Medical School, University of Pisa, Pisa, Italy Resicency in Internal Medicine 2003 Internal Medicina
Medical School, University of Pisa, Pisa, Italy Master in Hepatology 2002 Hepatology
Medical School, University of Pisa, Pisa Italy Master Degree in Medicine and Surgery 1997 Medicine and Surgery
RESEARCH, TEACHING, or OTHER INTERESTS
Transplantation, Gastroenterology
70
Scopus Publications
Scopus Publications
Machine perfusion improves outcomes of liver recipients via non-immunomodulatory effects Giulia Cirillo, Serena Babboni, Daniele Pezzati, Emanuele Balzano, Giovanni Tincani, Jessica Bronzoni, Arianna Trizzino, Lorenzo Petagna, Paola Carrai, Stefania Petruccelli, Gabriele Catalano, Ranka Vukotic, Serena Del Turco, Giuseppina Basta, Davide Ghinolfi Hepatobiliary and Pancreatic Diseases International, 2026
Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study Raffaella Viganò, Alessandro Loglio, Clara Dibenedetto, Paola Carrai, Silvia Martini, Ilaria Lenci, Bianca Magro, Sara Conti, Paolo Angelo Cortesi, Chiara Mazzarelli, Chiara Becchetti, Giovanni Perricone, Monica Cucco, Marco Carbone, Donatella Cocchis, Elisa Farina, Luisa Pasulo, Mauro Viganò, Michele Sagasta, Elisabetta Degasperi, Davide Ghinolfi, Pietro Lampertico, Stefano Fagiuoli, Luca Saverio Belli, and Alimentary Pharmacology and Therapeutics, 2026 Background & AimsDespite recommendations from scientific societies that hepatitis B immunoglobulin (HBIG) can be safely discontinued, centres across Europe continue to use the combination nucleoside analogues (NAs) plus HBIG for long‐term prophylaxis against hepatitis B virus (HBV) recurrence after liver transplant (LT). The aim of this study was to evaluate the safety of HBIG withdrawal in a cohort of LT recipients on long‐term HBIG+NAs.MethodsAll patients under third‐generation NAs + HBIG and who adhered to the INSIGHT‐B protocol were followed up after HBIG withdrawal, in a multicentre, prospective, Italian cohort study, to evaluate the risk of HBV reactivation. The probability of HBsAg reappearance after HBIG withdrawal, stratified by presence of HCC at LT, was estimated through Kaplan–Meier curves and Log‐rank tests.ResultsBetween February 2021 and January 2024, 222 liver transplant (LT) recipients withdrew HBIG 11.6 (IQR 6.7–17.0) years after LT and were followed up for a median time of 24 months. After HBIG withdrawal, Hepatitis B surface antigen (HBsAg) reappearance was observed in 12 patients (5.4%) with a cumulative 1‐, 2‐ and 3‐year recurrence rate of 4.08%, 5.36% and 6.89% respectively. HBsAg serum levels remained very low over the entire period of observation (median 9 months, range 3–20), and in four cases fluctuated around the detectability threshold. In all cases, HBV‐DNA persisted undetectable, liver function tests (LFTs) remained within the normal range, and neither HBV‐related hepatitis nor HCC were observed. No baseline patients' features were found to be significantly associated with the likelihood of HBsAg reappearance after HBIG withdrawal, including the presence of HCC at transplantation.ConclusionsHBIG could be safely withdrawn in HBV mono‐infected LT recipients on long‐term combination HBIG plus third generation NAs.
Cytokines Adsorption During Ex Situ Machine Perfusion of Liver Grafts from Elderly Donors: A Pilot, Prospective, Randomized Study Giulia Cirillo, Lorenzo Bernardi, Daniele Pezzati, Maria Franzini, Emanuele Balzano, Giovanni Tincani, Jessica Bronzoni, Caterina Martinelli, Arianna Trizzino, Lorenzo Petagna, Paola Carrai, Stefania Petruccelli, Ranka Vukotic, Erlis Uruci, Matilde Masini, Serena Babboni, Serena Del Turco, Riccardo Morganti, Vincenzo De Tata, Aldo Paolicchi, Giandomenico Biancofiore, Adriano Peris, Chiara Lazzeri, Giuseppina Basta, Davide Ghinolfi Life, 2026 Ischemia–reperfusion injury (IRI) is a mechanism based on inflammatory mediators’ release and activation of effectors of damage. Studies showed a correlation between cytokine, severity of damage, and post-operative outcomes. Ex situ perfusion may work as a platform for the treatment of IRI mechanisms, such as the removal of cytokines using cytokine adsorption (CA). We assessed the safety and benefits of an integrated CA during ex situ dual-oxygenated hypothermic (D-HOPE) and normothermic perfusion (NMP). During the period of July 2021–December 2023, 84 octogenarian liver grafts, suitable for transplantation, were considered: 12 were randomized to D-HOPE or NMP with or without CA (D-HOPE + CA, D-HOPE, NMP + CA, NMP groups, n = 3 each) and compared to 72 performed using grafts preserved in static cold storage (SCS). IL-1, IL-6, IL-10, and TNF-a perfusate concentrations were evaluated together with perfusion parameters and post-operative outcomes. Perfusion procedures were unaffected by CA integration. In NMP, cytokine levels were 10–40 times higher than in healthy subjects and 20–50 times higher than D-HOPE. Cytokines were removed both in D-HOPE and NMP, but the concentration-dependent mechanisms of action of CA led to more remarkable removal in NMP. IL-10 and TNF-a concentrations were significantly lower in NMP + CA than in NMP. The application of CA was associated with significantly higher arterial flows both in D-HOPE and NMP, and reduced neutrophil infiltration in NMP. No differences in post-operative outcomes were found among groups. In conclusion, cytokine adsorption during ex situ machine perfusion of liver grafts from elderly donors is safe and feasible and is associated with modulation of inflammatory mediators and perfusion dynamics. These findings are hypothesis-generating, and larger studies are required to determine the clinical impact of this strategy.
Association of perfusate cytokine concentrations during liver graft ex situ normothermic perfusion to donor type and postoperative outcomes Daniele Pezzati, Francesco Torri, Maria Franzini, Emanuele Balzano, Gabriele Catalano, Giovanni Tincani, Jessica Bronzoni, Caterina Martinelli, Arianna Trizzino, Lorenzo Petagna, Paola Carrai, Stefania Petruccelli, Matilde Masini, Maria Isabella Rotondo, Serena Babboni, Serena Del Turco, Riccardo Morganti, Vincenzo De Tata, Giandomenico Biancofiore, Adriano Peris, Chiara Lazzeri, Giuseppina Basta, Aldo Paolicchi, Davide Ghinolfi Liver Transplantation, 2025 Background: The use of the so-called extended criteria donors increases the number of grafts available for transplantation. Many studies reported their good outcomes but their use is debated due to increased risk of complications. Ex situ liver perfusion has reduced graft discard rate and helped to test their function before implantation. Cytokines are known to be involved in ischemia reperfusion injury but their potential to predict liver function during normothermic machine perfusion (NMP) has not been fully investigated. The aim of this study was to compare cytokines levels during NMP in 3 different types of donors (DBD, DCD II, DCD III) and correlate these data to postoperative clinical and biochemical outcomes. Methods: All DBDs older than 70 years and DCDs transplanted after NMP were included. IL-6, IL-10 and TNF-α were measured during NMP and correlated with clinical outcomes. Results: Thirty liver grafts were transplanted after NMP: 16 DBD, 7 DCD-II and 7 DCD-III. There were 6 cases of EAD (20.0%), 10 of PRS (33.3%) and 11 cases of AKI (36.7%), with no major differences among groups. A positive correlation was found between perfusate IL-6 levels and the bilirubin peak within 7 days after LT while IL-10 was associated with the ICU stay and TNF-α to the INR peak within 7 days. IL-6 was negatively associated to post-operative ALT levels, IL-10 to bilirubin peak. A correlation between higher IL-6 levels at 2h and graft loss was found. Conclusions. This is the first study to compare cytokines profile during NMP in three different types of donors and correlate it to clinical outcomes. A correlation between IL-6 concentration and graft failure was found. The role and the significate of inflammatory markers in MP perfusate and their potential to assess graft viability and the risk of post-LT complications has to be further addressed.
Liver transplantation for hepatitis D virus/hepatitis B virus coinfection in Italy: An intention-to-treat analysis of long-term outcomes Roberta Angelico, Silvia Trapani, Tommaso Maria Manzia, Ilaria Lenci, Paolo Grossi, Andrea Ricci, Patrizia Burra, Enzo Andorno, Salvatore Agnes, Sherrie Bhoori, Umberto Baccarani, Luca S. Belli, Paola Carrai, Lucio Caccamo, Amedeo Carraro, Matteo Cescon, Michele Colledan, Umberto Cillo, Luciano De Carlis, Nicola De Maria, Paolo De Simone, Fabrizio di Benedetto, Maria Francesca Donato, Giuseppe Maria Ettorre, Flaminia Ferri, Alfonso Galeota Lanza, Davide Ghinolfi, Antonio Grieco, Salvatore Gruttadauria, Simona Marenco, Silvia Martini, Vincenzo Mazzaferro, Adriano Pellicelli, Domenico Pinelli, Maria Rendina, Mario Rizzetto, Renato Romagnoli, Massimo Rossi, Francesco Paolo Russo, Laura Schiadà, Francesco Tandoi, Pierluigi Toniutto, Laura Turco, Giovanni Vennarecci, Mauro Viganò, Marco Vivarelli, Giuseppe Tisone, Giuseppe Feltrin, Alessandra Nardi, Mario Angelico American Journal of Transplantation, 2025 Patients with hepatitis D virus (HDV)/hepatitis B virus (HBV)-related end-stage liver disease candidates for liver transplantation (LT) have traditionally been regarded as a special population, although their outcomes are controversial. An intention-to-treat (ITT) analysis of long-term outcomes of HDV/HBV-coinfected patients waitlisted for LT in Italy, between 2011 and 2020, was performed and compared with HBV-monoinfected LT candidates. Of 1731 HBV-infected LT candidates, 1237 (71.5%) had HBV monoinfection and 494 (28.5%) HDV/HBV coinfection. At listing, HDV/HBV-coinfected patients were significantly younger, listed mainly for decompensated cirrhosis, and with fewer hepatocellular carcinoma (HCC) cases; (26% vs 65.8%; P <.0001) compared with HBV-monoinfected patients. HDV/HBV-coinfected patients showed better 5-year ITT survival (83.2%; 95% CI: 79.4%-83.4%, vs 71.6%; 95% CI: 68.8%-74.2%; P < .0001). ITT-multivariable analysis identified the presence of HCC, advanced recipient age, and high model for end-stage liver disease-Na scores as mortality risk factors. Five years after LT, 99.1% of HDV/HBV-coinfected patients received oral nucleos(t)ide analogs, with immunoglobulins against antigen of the hepatitis B virus in 91.8% of cases. HBV and HDV viral recurrences were 1.1% and 0.2%, respectively, whereas recurrent or de novo HCC were 8.9% and 0.3%, respectively. In Italy, HDV/HBV-coinfected patients waitlisted for LT showed more favorable outcomes compared with HBV-monoinfected patients, both before and after LT. These excellent results, from the largest cohort reported so far, suggest that HDV/HBV-coinfected LT recipients do not represent a risky population and may be considered for simpler long-term antiviral prophylactic strategies.
Ischemic Heart Disease in Liver Transplant Candidates With High Bleeding Risk: Any Way Out? Chiara Del Carlo, Lorenza Santoni, Iacopo Fabiani, Michele Coceani, Chiara Arzilli, Claudio Passino, Paola Carrai, Davide Ghinolfi, Giandomenico Luigi Biancofiore, Michele Emdin Jacc Case Reports, 2025 Coronary artery disease in candidates for liver transplantation is a real challenge because of the need to balance the risks of bleeding and thrombosis. Antiplatelet therapy, essential to prevent thrombotic events, may increase the risk of hemorrhagic complications, especially in the context of hepatic surgery. A 71-year-old woman with end-stage liver disease (ESLD) presented for a pretransplantation evaluation. She received a diagnosis of significant coronary artery disease (CAD), and a multidisciplinary discussion resulted in the option for an invasive treatment with several precautions to minimize her bleeding risk. Because of the intricacy of underlying comorbidities and the elevated perioperative risk, managing CAD in patients with ESLD is particularly challenging. More research and evidence are needed on treating CAD in this patient group. Patients with ESLD who are waiting for liver transplantation should have CAD actively screened. Multidisciplinary treatment is crucial to maximizing the results.
Perfusate Liver Arginase 1 Levels After End-Ischemic Machine Perfusion Are Associated with Early Allograft Dysfunction Giuseppina Basta, Serena Babboni, Daniele Pezzati, Serena Del Turco, Emanuele Balzano, Gabriele Catalano, Lara Russo, Giovanni Tincani, Paola Carrai, Stefania Petruccelli, Jessica Bronzoni, Caterina Martinelli, Simona Palladino, Arianna Trizzino, Lorenzo Petagna, Renato Romagnoli, Damiano Patrono, Giandomenico Biancofiore, Adriano Peris, Chiara Lazzeri, Davide Ghinolfi Biomedicines, 2025 Background/Objectives: The rising use of liver grafts from donation after circulatory death (DCD) has been enabled by advances in normothermic regional perfusion (NRP) and machine perfusion (MP) technologies. We aimed to identify predictive biomarkers in DCD grafts subjected to NRP, followed by randomization to either normothermic machine perfusion (NMP) or dual hypothermic oxygenated perfusion (D-HOPE). Methods: Among 57 DCD donors, 32 liver grafts were transplanted, and recipients were monitored for one week post-transplant. Biomarkers linked with oxidative stress, hepatic injury, mitochondrial dysfunction, inflammation, regeneration, and autophagy were measured during NRP, end-ischemic MP, and one week post-transplant. Results: Arginase-1 (ARG-1) levels were consistently higher in discarded grafts and in recipients who later developed early allograft dysfunction (EAD). Specifically, ARG-1 levels at the end of MP correlated with markers of hepatic injury. Receiver operating characteristic analysis indicated that ARG-1 at the end of MP had a good predictive accuracy for EAD (AUC = 0.713; p = 0.02). Lipid peroxidation (TBARS) elevated at the start of NRP, declined over time, with higher levels in D-HOPE than in NMP, suggesting a more oxidative environment in D-HOPE. Metabolites like flavin mononucleotide (FMN) and NADH exhibited significant disparities between perfusion types, due to differences in perfusate compositions. Inflammatory biomarkers rose during NRP and NMP but normalized post-transplantation. Regenerative markers, including osteopontin and hepatocyte growth factor, increased during NRP and NMP and normalized post-transplant. Conclusions: ARG-1 demonstrates strong potential as an early biomarker for assessing liver graft viability during perfusion, supporting timely and effective decision-making in transplantation.
Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus Cirrhosis Lisa M. van Velsen, Lisette A.P. Krassenburg, Grishma Hirode, Kosh Agarwal, Graham R. Foster, Zillah Cargill, Raoel Maan, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg, Robert J. de Knegt, Gonzalo Crespo, Jose L. Calleja, Alnoor Ramji, Giuseppina Brancaccio, Maria Cristina Morelli, Ilaria Lenci, Chiara Mazzarelli, Raffaella Vigano, Paolo Angeli, Patrizia Burra, Maria Francesca Donato, Paola Carrai, Silvia Martini, Paolo Caraceni, Francesco Paolo Russo, Harry L.A. Janssen, Bettina E. Hansen, Adriaan J. van der Meer, Jordan J. Feld, Milan J. Sonneveld Clinical Gastroenterology and Hepatology, 2025 BACKGROUND & AIMS: Sustained virological response (SVR) improves prognosis in patients with chronic hepatitis C virus (HCV) with compensated cirrhosis, but whether a similar benefit can be obtained in decompensated patients is controversial. We studied the association between SVR and liver-related events (LREs) in patients with decompensated HCV cirrhosis. METHODS: We included patients with decompensated HCV cirrhosis (Child-Turcotte-Pugh [CTP] ≥7 and/or history of decompensation) treated with direct-acting antivirals. The association between SVR and LREs, and between SVR-related change in Model for End-stage Liver Disease (MELD) score and LREs were assessed. RESULTS: In total, 914 patients were included, with a median age of 54.7 years; 45% had alcohol use disorder, 87% CTP-B, and the median MELD score was 12.1. SVR was achieved in 834 patients (91.2%), with a median follow-up of 28 months. The 3-year cumulative incidence of LREs was 47.5% in patients with SVR compared with 58.6% in those without (P < .001). Findings were consistent in multivariable analysis (adjusted hazard ratio [aHR], 0.692; P = .011). SVR was associated with a reduced risk of LREs in patients with a pretreatment MELD <15 (44.4% vs 57.6%; aHR, 0.601; P = .004), but not among patients with MELD ≥15 (62.8% vs 58.9%; aHR, 0.936; P = .801). Among patients with SVR, a ≥2-point decrease in MELD was observed in 23.4% and was not associated with a reduced risk of LREs (52.1% vs 50.7%; P = .473). Findings were consistent in multivariable analysis (aHR, 0.730; P = .122), and in patients with a pretreatment MELD score ≥15. CONCLUSIONS: SVR was associated with a reduced risk of LREs in patients with decompensated HCV cirrhosis with a MELD score <15, whereas no clinical benefit was observed in those with higher MELD scores despite an SVR-associated MELD decrease.
The importance of patient fitness in expert and multidisciplinary multiparametric management of HCC: a narrative review , Mario Masarone, Giuseppe Cabibbo, Riccardo Pravisani, Filippo Pelizzaro, Pietro Torre, Mauro Viganò, Alessandro Loglio, Alessandro Vitale, Marcello Persico Hepatoma Research, 2025 Hepatocellular carcinoma (HCC) management is a challenging task. Despite continuous efforts to develop more effective treatments, patient prognosis often remains poor. Recently, a new management concept - the “multiparametric therapeutic Hierarchy” - has been proposed, with the hypothetical advantage of avoiding the risk of undertreatment inherent in “classical” HCC management modalities while also minimizing the risk of overtreatment that may occur when inexperienced clinicians adopt overly aggressive treatment hierarchies. The “multiparametric” concept emphasizes a more comprehensive evaluation of each patient, focusing on their individual clinical presentation. Among the various factors considered, patient fitness plays a critical role. Here, fitness is understood as the set of patient-specific characteristics that can influence the outcomes of therapies within the hierarchical framework (or even preclude certain therapies altogether). This multifaceted concept extends beyond traditional “Performance Status” measurements, incorporating considerations of frailty and comorbidity. In this review, we explore the available evidence regarding the role of patient fitness within the multiparametric therapeutic hierarchy for HCC. Finally, we discuss fitness considerations across different levels of the therapeutic hierarchy, highlighting current evidence, existing challenges, and limitations, with the aim of providing new insights for physicians involved in HCC management.
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study Alessandro Vitale, Silvia Trapani, Francesco Paolo Russo, Luca Miele, Gianluca Svegliati Baroni, Giulio Marchesini, Patrizia Burra, Marco Salvatore Ottoveggio, Renato Romagnoli, Silvia Martini, Paolo De Simone, Paola Carrai, Matteo Cescon, Maria Cristina Morelli, Luciano De Carlis, Luca Belli, Salvatore Gruttadauria, Riccardo Volpes, Michele Colledan, Stefano Fagiuoli, Fabrizio Di Benedetto, Nicola De Maria, Giorgio Rossi, Lucio Caccamo, Francesca Donato, Giovanni Vennarecci, Giovan Giuseppe Di Costanzo, Marco Vivarelli, Amedeo Carraro, David Sacerdoti, Giuseppe Maria Ettorre, Valerio Giannelli, Salvatore Agnes, Antonio Gasbarrini, Massimo Rossi, Stefano Ginanni Corradini, Vincenzo Mazzaferro, Sherrie Bhoori, Tommaso Maria Manzia, Ilaria Lenci, Fausto Zamboni, Laura Mameli, Umberto Baccarani, Pierluigi Toniutto, Luigi Giovanni Lupo, Francesco Tandoi, Maria Rendina, Enzo Andorno, Edoardo Giovanni Giannini, Marco Spada, Ilaria Billato, Andrea Marchini, Pierluigi Romano, Giuseppina Brancaccio, Francesco D’Amico, Andrea Ricci, Massimo Cardillo, Umberto Cillo Jhep Reports, 2024
Oxidative stress–induced fibrinogen modifications in liver transplant recipients: unraveling a novel potential mechanism for cardiovascular risk Stefano Gitto, Claudia Fiorillo, Flavia Rita Argento, Eleonora Fini, Serena Borghi, Margherita Falcini, Davide Roccarina, Rosario La Delfa, Ludovica Lillo, Tommaso Zurli, Paolo Forte, Davide Ghinolfi, Paolo De Simone, Francesca Chiesi, Angelica Ingravallo, Francesco Vizzutti, Silvia Aspite, Giacomo Laffi, Erica Lynch, Stefania Petruccelli, Paola Carrai, Simona Palladino, Francesco Sofi, Laura Stefani, Amedeo Amedei, Simone Baldi, Arianna Toscano, Chloe Lau, Fabio Marra, Matteo Becatti Research and Practice in Thrombosis and Haemostasis, 2024
Trends in liver transplantation for primary sclerosing cholangitis Maria Cristina Morelli, Martina Gambato, Silvia Martini, Paola Carrai, Pierluigi Toniutto, Valerio Giannelli, Francesca Donato, Ilaria Lenci, Luisa Pasulo, Chiara Mazzarelli, Alberto Ferrarese, Maria Rendina, Antonio Grieco, Alfonso Galeota Lanza, Gianluca Svegliati Baroni, Nicola De Maria, Simona Marenco, Laura Mameli, Francesca Romana Ponziani, Giovanni Vitale, Patrizia Burra, Raffaella Viganò, Ezio Fornasiere, Elisa Catanzaro, Giuseppe Marrone, Martina Milana, Alberto Calleri, Chiara Scorzoni, Gabriella Frassanito, Raffaella Lionetti, Clara Dibenedetto Digestive and Liver Disease, 2024
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study Stefano GITTO, , Lucia GOLFIERI, Francesco SOFI, Maria R. TAMÈ, Giovanni VITALE, Nicola DE MARIA, Luca MARZI, Andrea MEGA, Giovanna VALENTE, Alberto BORGHI, Paolo FORTE, Matteo CESCON, Fabrizio DI BENEDETTO, Pietro ANDREONE, Marco PETRANELLI, Monica DINU, Paola CARRAI, Giulio ARCANGELI, Silvana GRANDI, Chloe LAU, Maria Cristina MORELLI, Paolo DE SIMONE, Francesca CHIESI, Fabio MARRA Minerva Gastroenterology, 2024
Physical activity in liver transplant recipients: a large multicenter study Stefano Gitto, Lucia Golfieri, Filippo Gabrielli, Margherita Falcini, Francesco Sofi, Maria Rosa Tamè, Nicola De Maria, Luca Marzi, Andrea Mega, Giovanna Valente, Alberto Borghi, Paolo Forte, Matteo Cescon, Fabrizio Di Benedetto, Pietro Andreone, Marco Petranelli, Maria Cristina Morelli, Paolo De Simone, Chloe Lau, Laura Stefani, Francesco Vizzutti, Francesca Chiesi, Fabio Marra, , Giovanni Vitale, Giacomo Bisonti, Filippo Schepis, Erica Villa, Guido Piai, Francesco Giuseppe Foschi, Paolo Magistri, Paola Carrai, Stefania Petruccelli, Marco Corsi, Edoardo Falconi, Roberto Palazzo Internal and Emergency Medicine, 2024
First-in-human liver transplantation from a centenarian deceased donor after brain death Paolo De Simone, Davide Ghinolfi, Simona Palladino, Gabriele Catalano, Caterina Martinelli, Juri Ducci, Jessica Bronzoni, Giovanni Tincani, Emanuele Balzano, Paola Carrai, Stefania Petruccelli, Daniela Campani, Laura Crocetti, Chiara Lazzeri, Giandomenico Biancofiore, Adriano Peris American Journal of Transplantation, 2024
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients Maria Rendina, Michele Barone, Chiara Lillo, Silvia Trapani, Lucia Masiero, Paolo Trerotoli, Francesca Puoti, Luigi Giovanni Lupo, Francesco Tandoi, Salvatore Agnes, Antonio Grieco, Enzo Andorno, Simona Marenco, Edoardo Giovanni Giannini, Umberto Baccarani, Pierluigi Toniutto, Amedeo Carraro, Antonio Colecchia, Matteo Cescon, Maria Cristina Morelli, Umberto Cillo, Patrizia Burra, Paolo Angeli, Michele Colledan, Stefano Fagiuoli, Luciano De Carlis, Luca Belli, Paolo De Simone, Paola Carrai, Fabrizio Di Benedetto, Nicola De Maria, Giuseppe Maria Ettorre, Valerio Giannelli, Salvatore Gruttadauria, Riccardo Volpes, Sveva Corsale, Vincenzo Mazzaferro, Sherrie Bhoori, Renato Romagnoli, Silvia Martini, Giorgio Rossi, Lucio Caccamo, Maria Francesca Donato, Massimo Rossi, Stefano Ginanni Corradini, Marco Spada, Giuseppe Maggiore, Giuseppe Tisone, Ilaria Lenci, Giovanni Vennarecci, Raffaella Tortora, Marco Vivarelli, Gianluca Svegliati Baroni, Fausto Zamboni, Laura Mameli, Silvio Tafuri, Simona Simone, Loreto Gesualdo, Massimo Cardillo, Alfredo Di Leo Frontiers in Immunology, 2023
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study Stefano Gitto, Lucia Golfieri, Nicolò Mannelli, Maria Rosa Tamè, Ivo Lopez, Roberta Ceccato, Stanislao Montanari, Margherita Falcini, Giovanni Vitale, Nicola De Maria, Danilo Lo Presti, Luca Marzi, Andrea Mega, Giovanna Valente, Alberto Borghi, Francesco Giuseppe Foschi, Silvana Grandi, Paolo Forte, Matteo Cescon, Fabrizio Di Benedetto, Pietro Andreone, Giulio Arcangeli, Paolo De Simone, Andrea Bonacchi, Francesco Sofi, Maria Cristina Morelli, Marco Petranelli, Chloe Lau, Fabio Marra, Francesca Chiesi, , Francesco Vizzutti, Vittoria Vero, Roberto Di Donato, Sonia Berardi, Paolo Pianta, Sharon D’Anzi, Filippo Schepis, Noemi Gualandi, Francesca Miceli, Erica Villa, Guido Piai, Marco Valente, Claudia Campani, Erica Lynch, Paolo Magistri, Carmela Cursaro, Annarita Chiarelli, Paola Carrai, Stefania Petruccelli, Monica Dinu, Giuditta Pagliai Liver International, 2022
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study Stefano Gitto, Paolo Magistri, Luca Marzi, Nicolò Mannelli, Nicola De Maria, Andrea Mega, Giovanni Vitale, Giovanna Valente, Francesco Vizzutti, Erica Villa, Fabio Marra, Pietro Andreone, Margherita Falcini, Barbara Catellani, Gian Piero Guerrini, Valentina Serra, Stefano Di Sandro, Roberto Ballarin, Guido Piai, Filippo Schepis, Marzia Margotti, Carmela Cursaro, Paolo De Simone, Stefania Petruccelli, Paola Carrai, Paolo Forte, Claudia Campani, Heinz Zoller, Fabrizio Di Benedetto Annals of Hepatology, 2022
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study Stefano Gitto, Nicola De Maria, Luca Marzi, Paolo Magistri, Margherita Falcini, Giovanni Vitale, Tiziana Olivieri, Gian Piero Guerrini, Valentina Serra, Paolo Forte, Paola Carrai, Paolo De Simone, Andrea Mega, Heinz Zoller, Guido Piai, Filippo Schepis, Margherita Marocchi, Erica Villa, Fabio Marra, Pietro Andreone, Fabrizio Di Benedetto, Francesco Vizzutti, Giacomo Laffi, Edoardo Borelli, Roberto Ballarin, Giuseppe Tarantino, Stefano Di Sandro, Rachele Puntili, Stefania Petruccelli, Giovanna Valente, Laura Turco European Journal of Internal Medicine, 2020
Outcomes of Liver Transplant for Adults With Wilson’s Disease Alberto Ferrarese, Maria Cristina Morelli, Paola Carrai, Martina Milana, Mario Angelico, Giovanni Perricone, Luca Saverio Belli, Giuseppe Marrone, Antonio Grieco, Silvia Martini, Matteo Angelo Manini, Stefano Fagiuoli, Pierluigi Toniutto, Alfonso Galeota Lanza, Sherrie Bhoori, Salvatore Petta, Edoardo G. Giannini, Patrizia Burra Liver Transplantation, 2020
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program Vincenza Calvaruso, Chiara Mazzarelli, Laura Milazzo, Lorenzo Badia, Luisa Pasulo, Giovanni Guaraldi, Raffaella Lionetti, Erica Villa, Vanni Borghi, Paola Carrai, Alfredo Alberti, Marco Biolato, Guido Piai, Marcello Persico, Teresa Santantonio, Martina Felder, Mario Angelico, Marzia Montalbano, Rossella Letizia Mancusi, Antonio Grieco, Elena Angeli, Gianpiero D’Offizi, Stefano Fagiuoli, Luca Belli, Gabriella Verucchi, Massimo Puoti, Antonio Craxì Scientific Reports, 2019
Platelets and hepatocellular cancer: Bridging the bench to the clinics Quirino Lai, Alessandro Vitale, Tommaso Manzia, Francesco Foschi, Giovanni Levi Sandri, Martina Gambato, Fabio Melandro, Francesco Russo, Luca Miele, Luca Viganò, Patrizia Burra, Edoardo Giannini, and Cancers, 2019
Nonagenarian Grafts for Liver Transplantation Davide Ghinolfi, Daniele Pezzati, Erion Rreka, Emanuele Balzano, Gabriele Catalano, Laura Coletti, Giovanni Tincani, Paola Carrai, Stefania Petruccelli, Caterina Martinelli, Rebecca Aglietti, Maria Lucia Bindi, Riccardo Morganti, Giandomenico Biancofiore, Paolo De Simone Liver Transplantation, 2019
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany Cristina Stasi, Caterina Silvestri, Roberto Berni, Maurizia Rossana Brunetto, Anna Linda Zignego, Cristina Orsini, Stefano Milani, Liana Ricciardi, Andrea De Luca, Pierluigi Blanc, Cesira Nencioni, Donatella Aquilini, Alessandro Bartoloni, Giampaolo Bresci, Santino Marchi, Franco Filipponi, Piero Colombatto, Paolo Forte, Andrea Galli, Sauro Luchi, Silvia Chigiotti, Alessandro Nerli, Giampaolo Corti, Rodolfo Sacco, Paola Carrai, Angelo Ricchiuti, Massimo Giusti, Paolo Almi, Andrea Cozzi, Silvia Carloppi, Giacomo Laffi, Fabio Voller, Francesco Cipriani Current Medical Research and Opinion, 2019
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis Maria Guarino, Luca Viganò, Francesca Romana Ponziani, Edoardo Giovanni Giannini, Quirino Lai, Filomena Morisco, Alessandro Vitale, Francesco Paolo Russo, Umberto Cillo, Patrizia Burra, Claudia Mescoli, Martina Gambato, Anna Sessa, Giuseppe Cabibbo, Mauro Viganò, Giovanni Galati, Erica Villa, Massimo Iavarone, Giuseppina Brancaccio, Maria Rendina, Luigi G. Lupo, Francesco Losito, Fabio Fucilli, Marcello Persico, Roberta D’Ambrosio, Angelo Sangiovanni, Alessandro Cucchetti, Franco Trevisani e Matteo Renzulli, Luca Miele, Antonio Grieco, Gian Lodovico Rapaccini, Maurizio Pompili, Antonio Gasbarrini, Giovanni Battista Levi Sandri, Fabio Melandro, Massimo Rossi, Ilaria Lenci, Tommaso Maria Manzia, Raffaella Tortora, Giovan Giuseppe Di Costanzo, Rodolfo Sacco, Davide Ghinolfi, Erion Rreka, Paola Carrai, Natalia Simonetti, Carlo Sposito, Sherrie Bhoori, Stefano di Sandro, Francesco Giuseppe Foschi, Andrea Casadei Gardini, Daniele Nicolini, Susanna Mazzocato, Alba Kostandini, Paola Violi, Umberto Baccarani, Riccardo Pravisani, Valter Vincenzi Digestive and Liver Disease, 2018
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis R. Vukotic, F. Conti, S. Fagiuoli, M. C. Morelli, L. Pasulo, M. Colpani, F. G. Foschi, S. Berardi, P. Pianta, M. Mangano, M. F. Donato, F. Malinverno, S. Monico, M. Tamè, G. Mazzella, L. S. Belli, R. Viganò, P. Carrai, P. Burra, F. P. Russo, I. Lenci, P. Toniutto, M. Merli, L. Loiacono, R. Iemmolo, A. M. Degli Antoni, A. Romano, A. Picciotto, M. Rendina, P. Andreone, AISF‐SOFOLT Study group Journal of Viral Hepatitis, 2017
The "You Are Not Alone" Care Program for Liver Transplantation L. Baldoni, P. De Simone, R. Paganelli, L. Traballoni, M. Elisei, L. Bindi, J. Ducci, P. Carrai, M. Bisá, L. Coletti, S. Petruccelli, M. Masetti, A. Padovan, F. Coscetti, F. Filipponi Transplantation Proceedings, 2008
